Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and pharmaceutical compositions for the treatment of respiratory tract infections

a technology of respiratory tract infections and pharmaceutical compositions, applied in the direction of antibacterial agents, aerosol delivery, peptide/protein ingredients, etc., can solve the problems of irritability, poor appetite, runny or stuffy nose,

Inactive Publication Date: 2013-06-13
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method for using a substance called flagellin to treat pneumonia caused by a bacteria called Streptococcus pneumoniae. The researchers found that flagellin can activate the immune system and increase resistance to the bacteria. They also found that flagellin can protect against other respiratory infections, including those caused by viruses and fungi. The patent also describes how to make the flagellin substance and how to use it to treat pneumonia. Overall, the patent shows that flagellin can be a promising treatment for pneumonia and other respiratory infections.

Problems solved by technology

Symptoms of upper respiratory tract infection include runny or stuffy nose, irritability, restlessness, poor appetite, decreased activity level, coughing, and fever.
Unfortunately, in regard to certain infections, there are no therapies available, infections have been proven to be refractory to therapies, or the occurrence of side effects outweighs the benefits of the administration of a therapy to a subject.
The use of anti-bacterial agents for treatment of bacterial respiratory tract infections may also produce side effects or result in resistant bacterial strains.
The administration of antifungal agents may cause renal failure or bone marrow dysfunction and may not be effective against fungal infection in subjects with suppressed immune systems.
Thus, as a result of drug resistance, many infections prove refractory to a wide array of standard treatment protocols.
Various cells of the pulmonary tract including the epithelial cells express TLR5 but the modulation of the TLR5 signalling pathway has not yet been investigated for the treatment of respiratory tract infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and pharmaceutical compositions for the treatment of respiratory tract infections
  • Methods and pharmaceutical compositions for the treatment of respiratory tract infections

Examples

Experimental program
Comparison scheme
Effect test

example

[0078]Material & Methods

[0079]Bacterial Preparation:

[0080]Streptococcus pneumoniae serotype 1 (clinical isolate E1586) was obtained from the National Reference Laboratory—Ministry of Health, Uruguay (39). Working stocks were prepared as follows. Todd Hewitt Yeast Broth (THYB) (Sigma-Aldrich, St. Louis—Mo., USA) was inoculated with fresh colonies of S. pneumoniae grown in blood-agar plates, and incubated at 37° C. until the culture reached OD600nm of 0.7-0.9 units. Cultures were stored at −80° C. in THYB+glycerol 12% (v / v) up to 3 months. For mouse infection, working stocks were thawed and washed with sterile physiological saline solution (saline) and diluted to the appropriate concentration. Number of bacteria in stocks was confirmed by plating serial dilutions onto blood agar plates.

[0081]Proteins:

[0082]Native flagellin (FliC) from Salmonella enterica Serovar Typhimurium SIN22, or recombinant flagellins (FliCΔ174-400 and FliCΔ174-400 / 89-96*) were prepared as previously described (2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Compositionaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.

Description

FIELD OF THE INVENTION[0001]The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.BACKGROUND OF THE INVENTION[0002]Respiratory tract infections are common infections of the upper respiratory tract (e.g., nose, ears, sinuses, and throat) and lower respiratory tract (e.g., trachea, bronchial tubes, and lungs). Symptoms of upper respiratory tract infection include runny or stuffy nose, irritability, restlessness, poor appetite, decreased activity level, coughing, and fever.[0003]Viral respiratory tract infections cause and / or are associated with sore throats, colds, croup, and the flu. Examples of viruses that cause upper and lower respiratory tract infections include rhinoviruses and influenza viruses A and B.[0004]Common respiratory bacterial infections cause and / or associated with, for ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16
CPCC12Q1/18A61K38/164A61P11/00A61P31/04A61P31/10A61P31/12Y02A50/30A61K9/0043A61K9/007A61K9/08A61K9/12
Inventor SIRARD, JEAN-CLAUDECHABALGOITY, JOSE A.
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com